Micelle-like nanoparticles as siRNA and miRNA carriers for cancer therapy

Costa, Daniel F.; Torchilin, Vladimir P.

doi:10.1007/s10544-018-0298-0

Cited by 23 publications

(13 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Micelles are spherical structures composed of monolayer phospholipids with a hydrophobic core and hydrophilic shell, which are automatically assembled by amphiphilic copolymers in water. They are approximately 10–100 nm in diameter, and they can be used as carriers of siRNA and miRNA for cancer treatment ( Costa and Torchilin, 2018 ). The hydrophilic shell reduces the phagocytosis of the nanoparticles by RES and prolongs the half-life of the drug ( Yousefpour Marzbali and Yari Khosroushahi, 2017 ).…”

Section: Delivery Systemsmentioning

confidence: 99%

Insight Into the Prospects for RNAi Therapy of Cancer

et al. 2021

View full text Add to dashboard Cite

RNA interference (RNAi), also known as gene silencing, is a biological process that prevents gene expression in certain diseases such as cancer. It can be used to improve the accuracy, efficiency, and stability of treatments, particularly genetic therapies. However, challenges such as delivery of oligonucleotide drug to less accessible parts of the body and the high incidence of toxic side effects are encountered. It is therefore imperative to improve their delivery to target sites and reduce their harmful effects on noncancerous cells to harness their full potential. In this study, the role of RNAi in the treatment of COVID-19, the novel coronavirus disease plaguing many countries, has been discussed. This review aims to ascertain the mechanism and application of RNAi and explore the current challenges of RNAi therapy by identifying some of the cancer delivery systems and providing drug information for their improvement. It is worth mentioning that delivery systems such as lipid-based delivery systems and exosomes have revolutionized RNAi therapy by reducing their immunogenicity and improving their cellular affinity. A deeper understanding of the mechanism and challenges associated with RNAi in cancer therapy can provide new insights into RNAi drug development.

show abstract

Section: Delivery Systemsmentioning

confidence: 99%

Insight Into the Prospects for RNAi Therapy of Cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…However, there are still significant challenges to overcome to ensure the efficient delivery of miRNA to the tumor in vivo, for example, off-target effects, poor serum stability, and ineffective, poorly selective cellular entry. Hence, the development of novel drug delivery systems with the capacity to target-directed transport and protection of such cargos is mandatory [ 100 ].…”

Section: Therapeutic Combination Of Icd and Mirnas: A New Opportunitymentioning

confidence: 99%

Damage-Associated Molecular Patterns Modulation by microRNA: Relevance on Immunogenic Cell Death and Cancer Treatment Outcome

Lamberti

Nigro

Casolaro

et al. 2021

Cancers

View full text Add to dashboard Cite

Immunogenic cell death (ICD) in cancer is a functionally unique regulated form of stress-mediated cell death that activates both the innate and adaptive immune response against tumor cells. ICD makes dying cancer cells immunogenic by improving both antigenicity and adjuvanticity. The latter relies on the spatiotemporally coordinated release or exposure of danger signals (DAMPs) that drive robust antigen-presenting cell activation. The expression of DAMPs is often constitutive in tumor cells, but it is the initiating stressor, called ICD-inducer, which finally triggers the intracellular response that determines the kinetics and intensity of their release. However, the contribution of cell-autonomous features, such as the epigenetic background, to the development of ICD has not been addressed in sufficient depth. In this context, it has been revealed that several microRNAs (miRNAs), besides acting as tumor promoters or suppressors, can control the ICD-associated exposure of some DAMPs and their basal expression in cancer. Here, we provide a general overview of the dysregulation of cancer-associated miRNAs whose targets are DAMPs, through which new molecular mediators that underlie the immunogenicity of ICD were identified. The current status of miRNA-targeted therapeutics combined with ICD inducers is discussed. A solid comprehension of these processes will provide a framework to evaluate miRNA targets for cancer immunotherapy.

show abstract

“…In combination with chemotherapeutics, it can improve targeting selectivity and counterbalance drug resistance, thereby increasing therapeutic efficacy synergistically. Furthermore, combination therapy can enable the reduction of the required dose of individual chemotherapeutic agents, which consequently reduces potential adverse drug reactions [87,347]. Bcl-2 siRNA and PTX coadministered in pH-sensitive liposomes exhibited a marked antitumor effect in melanoma cells compared with that found when free PTX was applied [348].…”

Section: Multifunctional Delivery Systemsmentioning

confidence: 99%

Nanotechnology approaches in the current therapy of skin cancer

Borgheti-Cardoso

Viegas

Silvestrini

et al. 2020

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

Skin cancer is a high burden disease with a high impact on global health. Conventional therapies have several drawbacks; thus, the development of effective therapies is required. In this context, nanotechnology approaches are an attractive strategy for cancer therapy because they enable the efficient delivery of drugs and other bioactive molecules to target tissues with low toxic effects. In this review, nanotechnological tools for skin cancer will be summarized and discussed. First, pathology and conventional therapies will be presented, followed by the challenges of skin cancer therapy. Then, the main features of developing efficient nanosystems will be discussed, and next, the most commonly used nanoparticles (NPs) described in the literature for skin cancer therapy will be presented. Subsequently, the use of NPs to deliver chemotherapeutics, immune and vaccine molecules and nucleic acids will be reviewed and discussed as will the combination of physical methods and NPs. Finally, multifunctional delivery systems to codeliver anticancer therapeutic agents containing or not surface functionalization will be summarized.

show abstract

Micelle-like nanoparticles as siRNA and miRNA carriers for cancer therapy

Cited by 23 publications

References 111 publications

Insight Into the Prospects for RNAi Therapy of Cancer

Insight Into the Prospects for RNAi Therapy of Cancer

Damage-Associated Molecular Patterns Modulation by microRNA: Relevance on Immunogenic Cell Death and Cancer Treatment Outcome

Nanotechnology approaches in the current therapy of skin cancer

Contact Info

Product

Resources

About